Management of arterial hypertension in obese patients

Current Hypertension Reports

Volumn 9, Issue 6, 2007, Pages 491-497

  Wenzel, Ulrich O ^a   Krebs, Christian ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; GLITAZONE DERIVATIVE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOOP DIURETIC AGENT; LOSARTAN; PLACEBO; RAMIPRIL; RENIN INHIBITOR; ROSIGLITAZONE; SIBUTRAMINE; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG; VALSARTAN;

ADD ON THERAPY; ADIPOSE TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG CHOICE; DRUG INDICATION; DRUG SAFETY; HEMODYNAMICS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; METABOLIC REGULATION; MONOTHERAPY; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM RETENTION; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; OBESITY; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 38049110261     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0090-7     Document Type: Review

References (53)

1. Jordan J, Engeli S, Redon J, et al.: European Society of Hypertension Working Group on Obesity: background, aims and perspectives. J Hypertens 2007, 25:897-900.
2. Doll S, Paccaud F, Bovet P, et al.: Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord 2002, 26:48-57.
3. Bramlage P, Pittrow D, Wittchen HU, et al.: Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904-910.
4. Frohlich ED: Clinical management of the obese hypertensive patient. Cardiol Rev 2002, 10:127-138.
5. Dentali F, Sharma AM, Douketis JD: Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep 2005, 7:330-336.
6. Wenzel UO, Krebs C: Treatment of arterial hypertension in obese patients. Contrib Nephrol 2006, 151:230-242.
7. Rocchini AP: Cardiovascular regulation in obesity-induced hypertension. Hypertension 1992, 19(1 Suppl):156-60.
8. Sharma AM: Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004, 44:12-19.
9. Boustany CM, Bharadwaj K, Daugherty A, et al.: Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 2004, 287:R943-949.
10. Wofford MR, Hall JE: Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004, 10:3621-3637.
11. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA 2003, 289:2560-2572.
12. Sharma AM, Rossner S: Who cares about the obese hypertensive patient? J Intern Med 2002, 251:369-371.
13. Engeli S, Sharma AM: Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol 2002, 17:355-359.
14. Jones DW, Miller ME, Wofford MR, et al.: The effect of weight loss intervention on antihypertensive medication requirements in the Hypertension Optimal Treatment (HOT) study. Am J Hypertens 1999, 12(12 Pt 1-2):1175-1180.
15. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000, 894:i-xii, 1-253.
16. Sjostrom L, Lindroos AK, Peltonen M, et al.: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693.
17. Aucott L, Poobalan A, Smith WC, et al.: Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 2005, 45:1035-1041.
18. Basso N, Terragno NA: History about the discovery of the renin-anglotensin system. Hypertension 2001, 38:1246-1249.
19. Wenzel UO: Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies. Contrib Nephrol 2001, 135:200-211.
20. Wolf G, Butzmann U, Wenzel UO: The renin-anglotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003, 93:P3-13.
21. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
22. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004, 64:2537-2565.
23. McFarlane SI, Provilus A, Shin JJ: Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) Trial. J Cardiometab Syndr 2007, 2:149-150.
24. Sharma AM, Pischon T, Engeli S, Scholze J: Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001, 19:667-674.
25. Zanella MT, Kohlmann O Jr, Ribeiro AB: Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001, 38(3 Pt 2):705-708.
26. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
27. Grassi G, Seravalle G, Dell'Oro R, et al.: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003, 21:1761-1769.
28. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
29. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005, 67:799-812.
30. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
31. Benson SC, Pershadsingh HA, Ho CI, et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43:993-1002.
32. Schupp M, Janke J, Clasen R, et al.: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109:2054-2057.
33. Schupp M, Lee LD, Frost N, et al.: Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006, 47:586-589.
34. Benndorf RA, Rudolph T, Appel D, et al.: Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006, 55:1159-1164.
35. Müller DN, Luft FC: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1:221-228.
36. Huang Y, Wongamorntham S, Kasting J, et al.: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006, 69:105-113.
37. Krebs C, Hamming I, Sadaghiani S, et al.: Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007, Epub ahead of print.
38. Staessen JA, Li Y, Richart T: Oral renin inhibitors. Lancet 2006, 368:1449-1456.
39. Jordan J, Engeli S, Boye SW, et al.: Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047-1055.
40. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
41. Kostis JB, Wilson AC, Freudenberger RS, et al.: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005, 95:29-35.
42. Aksnes TA, Kjeldsen SE, Rostrup M, et al.: Impact of new-onset diabetes melfitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007, 50:467-473.
43. Wenzel UO: Aldosterone and progression of renal disease. Curr Opin Nephrol Hypertens 2007, In press.
44. Calhoun DA: Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 2006, 48:387-396.
45. Saha C, Eckert GJ, Ambrosius WT, et al.: Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481-487.
46. Sharma AM, Pischon T, Hardt S, et al.: Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001, 37:250-254.
47. Scholze J, Grimm E, Herrmann D, et al.: Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007, 115:1991-1998.
48. Lindholm LH, Carlberg B, Samuelsson O: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
49. Schmieder RE, Gatzka C, Schachinger H, et al.: Obesity as a determinant for response to antihypertensive treatment. BMJ 1993, 307:537-540.
50. White WB, Elliott WJ, Johnson MF, Black HR: Chrono-therapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. J Hum Hypertens 2001, 15:135-141.
51. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
52. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988, 31:415-420.
53. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1975.